{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:00:08Z","timestamp":1787061608943,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pleomorphic undifferentiated sarcoma (PUS) is a highly malignant soft tissue sarcoma typically found in the extremities or visceral organs, with primary pelvic cases being exceedingly rare and lacking standardized management strategies. We present the case of an elderly female with primary pelvic PUS who presented with right hip pain and progressive immobility. The tumor was large and involved surrounding tissues, making single-stage en bloc resection unfeasible. A multimodal strategy was implemented, including neoadjuvant chemotherapy combined with anlotinib, followed by drug-eluting bead transarterial chemoembolization (DEB-TACE), and subsequent resection and reconstruction with a 3D-printed pelvic prosthesis were performed. The patient achieved satisfactory functional recovery, and at the 12-month follow-up, there was no evidence of recurrence or metastasis and tumor was judged to have achieved pathological complete remission (pCR).This case demonstrates the feasibility of individualized multimodal therapy for complex pelvic PUS and provides valuable insights for managing this challenging entity.<\/jats:p>","DOI":"10.3389\/fonc.2025.1641058","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:13:05Z","timestamp":1765257185000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiahui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e23571","article-title":"Epidemiology of undifferentiated sarcomas: A rare entity","volume":"42","author":"Ali","year":"2024","journal-title":"J Of Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.029","article-title":"The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions","volume":"46","author":"Lee","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010084","article-title":"A planned multidisciplinary surgical approach to treat primary pelvic Malignancies","volume":"30","author":"Sambri","year":"2023","journal-title":"Curr Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.CC.19.00060","article-title":"Internal hemipelvectomy and reconstruction assisted by 3D printing technology using premade intraoperative cutting and placement guides in a patient with pelvic sarcoma: A case report","volume":"9","author":"G\u00f3mez-Palomo","year":"2019","journal-title":"JBJS Case Connect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196411)17","article-title":"MALIGNANT FIBROUS XANTHOMAS","volume":"17","author":"O\u2019Brien","year":"1964","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-1795","article-title":"Undifferentiated pleomorphic sarcoma of the extremity and trunk: a retrospective cohort study of 166 cases in a large institution","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/his.12267","article-title":"The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification","volume":"64","author":"Fletcher","year":"2014","journal-title":"Histopathology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3467","article-title":"Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and Malignant peripheral nerve sheath tumors: state of the art and perspectives","volume":"36","author":"Widemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2020.02.041","article-title":"Rare pancreatic metastasis of undifferentiated pleomorphic sarcoma originating from the pelvis: A case report","volume":"68","author":"Ohsawa","year":"2020","journal-title":"Int J Surg Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.184907","article-title":"High-grade undifferentiated pleomorphic sarcoma of the pelvis: A case report and review of literature","volume":"8","author":"Agafonoff","year":"2016","journal-title":"Urol Ann"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_201421","article-title":"Neoadjuvant chemotherapy, concurrent chemoradiation, and adjuvant chemotherapy for high-risk extremity soft tissue sarcoma","volume":"38","author":"Baldini","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from italian (ISG), spanish (GEIS), french (FSG), and polish (PSG) sarcoma groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh431","article-title":"Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma","volume":"15","author":"Grobmyer","year":"2004","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3420-8","article-title":"Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value","volume":"80","author":"Skubitz","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.02.020","article-title":"Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)","volume":"137","author":"Kushnir","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1038\/s41598-019-43794-3","article-title":"(Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series","volume":"9","author":"Nevala","year":"2019","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000787","article-title":"Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study","volume":"5","author":"Constantinidou","year":"2020","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.004","article-title":"Towards the standard use of (neo)adjuvant chemotherapy in selected localised soft tissue sarcoma at high risk of relapse: are we finally getting there","volume":"101","author":"Gronchi","year":"2018","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13569-018-0111-0","article-title":"Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure","volume":"9","author":"Savani","year":"2019","journal-title":"Clin Sarcoma Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2941","article-title":"Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S286322","article-title":"Efficacy and safety of anlotinib combined with liposomal doxorubicin followed by anlotinib maintenance in metastatic soft tissue sarcomas","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3390\/biology11070972","article-title":"Molecular mechanisms and key processes in interstitial, hemorrhagic and radiation cystitis","volume":"11","author":"Brossard","year":"2022","journal-title":"Biol (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393404","article-title":"Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000120601","article-title":"Complications of chemotherapy in patients with brain and spinal cord tumors","volume":"17","author":"Allen","year":"1991","journal-title":"Pediatr Neurosurg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/10715762.2017.1381694","article-title":"Attenuation of doxorubicin-induced cardiotoxicity and genotoxicity by an indole-based natural compound 3,3\u2019-diindolylmethane (DIM) through activation of Nrf2\/ARE signaling pathways and inhibiting apoptosis","volume":"51","author":"Hajra","year":"2017","journal-title":"Free Radic Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008361612767","article-title":"A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI)","volume":"10","author":"Vo\u00fbte","year":"1999","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20191020-00385","article-title":"Analysis of clinical efficacy, safety and prognosis of anlotinib hydrochloride in the treatment of advanced primary liver cancer","volume":"28","author":"Wang","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000542769","article-title":"A meta-analysis assessing the therapeutic efficacy and safety of anlotinib in combination with chemotherapy for small cell lung cancer","volume":"110","author":"Gao","year":"2025","journal-title":"Pharmacology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00520-025-09346-4","article-title":"Efficacy of triplet antiemetic prophylaxis against chemotherapy-induced nausea and vomiting in patients with soft tissue sarcomas receiving consecutive-day doxorubicin and ifosfamide therapy","volume":"33","author":"Yamada","year":"2025","journal-title":"Support Care Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctrv.2018.05.002","article-title":"Assessment of the risk of antiangiogenic agents before and after surgery","volume":"68","author":"Bailey","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4680-3","article-title":"Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma","volume":"22","author":"Jakob","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1037404","article-title":"A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities","volume":"54","author":"Haas","year":"2015","journal-title":"Acta Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00776-005-0900-1","article-title":"Preoperative embolization in spinal and pelvic metastases","volume":"10","author":"Wirbel","year":"2005","journal-title":"J Orthop Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/os.12336","article-title":"Selective arterial embolization for the treatment of sacral and pelvic giant cell tumor: A systematic review","volume":"9","author":"He","year":"2017","journal-title":"Orthop Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2530-3","article-title":"Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety","volume":"144","author":"Ni","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5301\/hipint.5000306","article-title":"Reconstruction of periacetabular tumours with saddle prosthesis or custom-made prosthesis, functional results and complications","volume":"26","author":"Dan\u0131\u015fman","year":"2016","journal-title":"Hip Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejso.2012.10.002","article-title":"Modular hemipelvic endoprosthesis reconstruction\u2013experience in 100 patients with mid-term follow-up results","volume":"39","author":"Ji","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-016-4805-4","article-title":"LUMiC(\u00ae) endoprosthetic reconstruction after periacetabular tumor resection: short-term results","volume":"475","author":"Bus","year":"2017","journal-title":"Clin Orthop Relat Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2021.05.007","article-title":"Clinical study of 3D printed personalized prosthesis in the treatment of bone defect after pelvic tumor resection","volume":"29","author":"Xu","year":"2021","journal-title":"J Orthop Translat"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2021.09.006","article-title":"A novel revision system for complex pelvic defects utilizing 3D-printed custom prosthesis","volume":"31","author":"Hao","year":"2021","journal-title":"J Orthop Translat"},{"key":"B46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/ORR.S99614","article-title":"3D-printed patient-specific applications in orthopedics","volume":"8","author":"Wong","year":"2016","journal-title":"Orthop Res Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5371\/hp.2020.32.1.1","article-title":"Three-dimensional-printing technology in hip and pelvic surgery: current landscape","volume":"32","author":"Woo","year":"2020","journal-title":"Hip Pelvis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.101B6.BJJ-2018-1472.R1","article-title":"Characterization of bone ingrowth and interface mechanics of a new porous 3D printed biomaterial: an animal study","author":"Tanzer","year":"2019","journal-title":"Bone Joint J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.99B2.BJJ-2016-0654.R1","article-title":"Reconstruction with 3D-printed pelvic endoprostheses after resection of a pelvic tumour","author":"Liang","year":"2017","journal-title":"Bone Joint J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.13107\/jocr.2025.v15.i06.5720","article-title":"Evaluating effectiveness, safety, and patient outcomes of 3D printing in orthopedic implant design and customization: A PRISMA-complaint systematic review","volume":"15","author":"Roy","year":"2025","journal-title":"J Orthop Case Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:13:08Z","timestamp":1765257188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":50,"alternative-id":["10.3389\/fonc.2025.1641058"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1641058","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1641058"}}